Price
$140.37-12.26%Social Signal Score
Analyst Ratings
25 analysts52-week range
- Last close
- $140.37
- Off 52w high
- -16.8%
- 200-day average
- $150.19
- vs 200-day
- -6.5%
Revenue
$15.03B+19.22%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vasant Narasimhan
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 75,267
- Beta
- 0.41
- Country
- CH
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.48
Financials
Revenue
$15.03B+19.2%Net Income
$1.20B+25.6%EBITDA
$5.37B+74.3%Free Cash Flow
$4.76B+77.7%EPS (diluted)
$0.63+57.5%Shares Outstanding (diluted)
1.91B-20.5%Operating Expenses
$8.23BCash & Debt
$8.97BReturn of Capital
$1.70BRevenue by Segment (annual)
$43.27BDividend per Share
$4.74Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $56.67B | $13.98B | $7.21 |
| 2024 | $51.72B | $11.94B | $5.92 |
| 2023 | $46.66B | $14.85B | $7.15 |
| 2022 | $43.46B | $6.96B | $3.19 |
| 2021 | $43.97B | $24.02B | $10.71 |
| 2020 | $49.90B | $8.07B | $3.54 |
| 2019 | $48.68B | $11.73B | $3.12 |
| 2018 | $46.10B | $12.61B | $5.44 |
| 2017 | $43.40B | $7.70B | $3.28 |
| 2016 | $49.44B | $6.71B | $2.82 |
| 2015 | $50.39B | $17.78B | $7.40 |
| 2014 | $53.63B | $10.21B | $4.21 |
| 2013 | $52.72B | $9.18B | $3.76 |
| 2012 | $51.97B | $9.27B | $3.93 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NVS's reported EPS growth of 4.8% a year over 13 years.
- EPS in 5 years
- $9.12
- Implied price
- $173.23
- Return from $151.98
- 2.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $86.12 — -43.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 13 | 16 | 19 | 22 | 25 |
|---|---|---|---|---|---|
| -5.2% | -13.9% | -10.3% | -7.1% | -4.4% | -1.9% |
| -0.2% | -9.4% | -5.5% | -2.2% | 0.7% | 3.3% |
| 4.8% | -4.9% | -0.8% | 2.7% | 5.7% | 8.4% |
| 9.8% | -0.3% | 3.9% | 7.5% | 10.7% | 13.6% |
| 14.8% | 4.2% | 8.6% | 12.4% | 15.8% | 18.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
95+8.78%Social Signal Score
Mentions (81)
- Newsmarketbeat.com·3d ago·Negative
Novartis Reaffirms Sales Targets as Drug Trial Results and FDA Talks Loom Novartis NYSE: NVS executives outlined a slate of upcoming drug-trial results and regulatory discussions across immunology, cardiovascular disease, oncology and neuroscience, while reiterating sales ambitions for several established medicines.
View source ↗ - Newsmarketbeat.com·3d ago·Negative
Novartis Says AI Is Speeding Drug Discovery and Trials, but Clinical Payoff Remains Unproven Novartis NYSE: NVS is applying artificial intelligence across drug research and clinical development, with executives reporting faster trial enrollment and drug candidate selection while cautioning that evidence of improved clinical success will take longer to emerge.
View source ↗ - Newsmarketbeat.com·3d ago·Negative
Novartis Targets 5% Annual Sales Growth Through 2031 Despite Patent Expirations Novartis NYSE: NVS expects annual sales growth of 5% from 2026 through 2031 and average mid-single-digit growth into the mid-2030s, as the drugmaker looks to offset patent expirations with newer medicines and its development pipeline.
View source ↗ - Newsseekingalpha.com·3d ago·Positive
Novartis AG (NVS) Meet Management: Growth Outlook, Cash Flow and R&D Pipeline Transcript Novartis AG (NVS) Meet Management: Growth Outlook, Cash Flow and R&D Pipeline Transcript
View source ↗ - Newsreuters.com·3d ago·Neutral
Novartis trims medium-term growth target, shares fall Novartis trims medium-term growth target, shares fall
View source ↗ - Newscnbc.com·3d ago·Neutral
Novartis bets on bigger blockbusters to power growth, forecasting 5% annual sales through 2031 Ahead of its Capital Markets Day on Thursday, Novartis upgraded its peak sales outlook for three of its blockbuster drugs to a combined $18 billion, up from a previous forecast of a combined $14 billion The company projected annual sales growth of 5% through 2031, slightly less ambitious than its previous guidance of 5% to 6% through 2030.
View source ↗ - Newswsj.com·3d ago·Negative
Novartis Sees Sales Growth Through 2031 The drugmaker expects annual sales growth of 5% from 2026 to 2031, from a previous forecast of 5% to 6% over the 2025-30 period.
View source ↗ - Newsreuters.com·3d ago·Neutral
Novartis targets 5% annual sales growth through 2031 Novartis targets 5% annual sales growth through 2031
View source ↗ - Newszacks.com·4d ago·Negative
NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica Novartis wins FDA approval for Cosentyx in adults with PMR, backed by phase III data showing sustained remission and steroid-sparing benefits.
View source ↗ - Newszacks.com·6d ago·Positive
Novartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HS NVS' Cosentyx gains a positive CHMP recommendation for adolescents with moderate to severe HS, potentially expanding treatment options in Europe.
View source ↗ - Newsfool.com·19d ago·Positive
Novartis: 3 Key Takeaways for Long-Term Investors Novartis raised full-year 2026 core operating income guidance after 4% sales growth. Rhapsido peak sales guidance increased to over $4 billion in combined indications.
View source ↗ - Newsreuters.com·20d ago·Negative
Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target
View source ↗ - Newsseekingalpha.com·22d ago·Positive
Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach Novartis is rated Hold, with a 12-month price target of $141.81, implying a 12.0% downside from the current share price. My model indicates near-term pressure on selected products, while projected pipeline revenue may support growth over the longer term. NVS trades at a discount to peers on forward P/E but at a premium on EV/EBITDA, producing mixed relative valuation signals.
View source ↗ - Newszacks.com·23d ago·Positive
All You Need to Know About Novartis (NVS) Rating Upgrade to Buy Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·23d ago·Positive
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newscnbc.com·23d ago·Negative
A pharma giant is moving past one patent cliff — but another is already looming Novartis CEO Vas Narasimhan told CNBC on Tuesday that its drug remibrutinib could become "one of our largest medicines in history." But analysts slashed the peak sales forecast for the drug after a late-stage clinical trial for patients with relapsing multiple sclerosis, while reaching its primary endpoint, appeared worse than expected.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Novartis AG (NVS) Q3 2026 Earnings Call Transcript Novartis AG ( NVS ) Q3 2026 Earnings Call October 27, 2026 8:00 AM EDT Company Participants Isabella Zinck - Investor Relations Manager Vasant Narasimhan - Chief Executive Officer Mukul Mehta - Chief Financial Officer Conference Call Participants Sachin Jain - BofA Securities, Research Division James Gordon - Barclays Bank PLC, Research Division Florent Cespedes - ODDO BHF Corporate & Markets, Research Division Graham Glyn Parry - Citigroup Inc.…
View source ↗ - Newsmarketbeat.com·26d ago·Neutral
What Novartis (NVS) Said on Its Q3 Earnings Call Novartis NYSE: NVS reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core operating income.
View source ↗ - Newszacks.com·26d ago·Neutral
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.
View source ↗ - Newsbenzinga.com·26d ago·Positive
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit Novartis AG (NYSE:NVS) reported mixed third-quarter earnings on Tuesday as the prized Avidity Biosciences deal worth $12 billion cost the company an estimated $1.9 billion in impairment charges, primarily driven by the timeline shifting due to additional clinical work to be completed.
View source ↗ - Newszacks.com·26d ago·Neutral
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newswsj.com·26d ago·Neutral
Novartis Raises Guidance Despite Trial Setbacks Hitting Profit The Swiss drugmaker cited solid sales growth and productivity gains, even as recent clinical-trial setbacks hit its bottom line in the third quarter.
View source ↗ - Newsseekingalpha.com·29d ago·Positive
Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript
View source ↗ - Newsmarketbeat.com·30d ago·Negative
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity Novartis NYSE: NVS presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton's tyrosine kinase inhibitor reduced relapse rates and MRI lesion activity versus teriflunomide in the REMODEL-1 and REMODEL-2 studies.
View source ↗ - Newsreuters.com·30d ago·Negative
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
View source ↗ - Newsreuters.com·30d ago·Negative
Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows
View source ↗ - Newszacks.com·31d ago·Neutral
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics Evaluate the expected performance of Novartis (NVS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
View source ↗ - Newsseekingalpha.com·34d ago·Neutral
Novartis: The Sell-Off Creates An Attractive Entry Point On October 27, Novartis will report its results for the third quarter. As a reminder, its Q2 revenue rose 10.6% quarter-over-quarter to $14.95 billion, primarily due to the strong performance of the oncology portfolio and Cosentyx. On September 18, 2026, the EMA's CHMP adopted a positive opinion recommending approval of Cosentyx for patients suffering from polymyalgia rheumatica.
View source ↗ - Newsreuters.com·37d ago·Neutral
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
View source ↗ - Newszacks.com·45d ago·Negative
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.
View source ↗ - Newsreuters.com·46d ago·Negative
US FDA expands use of Novartis drug for chronic skin condition The US Food and Drug Administration has expanded the use of Novartis' drug to treat adults with a chronic skin condition that causes recurring itchy welts, the Swiss drugmaker said on Wednesday.
View source ↗ - Newszacks.com·48d ago·Positive
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
View source ↗ - Newscnbc.com·51d ago·Negative
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals Swiss Novartis is entering a licensing agreement with a Chinese biotech worth as much as $7.8 billion. It comes after several pharma peers announced deals with China-based drug developers over the past two weeks.
View source ↗ - Newswsj.com·51d ago·Negative
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal Abogen said its lead drug has potential to transform the treatment landscape for patients with autoimmune diseases.
View source ↗ - Newsreuters.com·51d ago·Negative
Novartis signs mRNA deal for about $7.8 billion with China's Abogen Chinese biotech company Abogen said on Friday it signed a licensing deal worth about $7.8 billion with Swiss drug maker Novartis to advance RNA-based therapy.
View source ↗ - Newszacks.com·62d ago·Neutral
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
View source ↗ - Newsreuters.com·67d ago·Negative
Novartis halts ALS drug development after mid-stage trial failure Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals in a mid-stage study, marking the latest disappointment for the Swiss drugmaker this year.
View source ↗ - Newswsj.com·68d ago·Neutral
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
View source ↗ - Newsfool.com·69d ago·Negative
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. Novartis recently announced bad news for its Lp(a)-lowering drug, pelacarsen. Lilly is also developing a therapy for lowering Lp(a).
View source ↗ - Newsbarrons.com·72d ago·Negative
Novartis: More Pain on the Way? The bad diagnoses just keep on coming for the Swiss drugmaker.
View source ↗ - Newsgurufocus.com·72d ago·Negative
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning Novartis (NVS), the global innovative-medicines company, confronted sharper questions over its dealmaking strategy Friday after clinical setbacks weakened confi
View source ↗ - Newsreuters.com·72d ago·Negative
Focus: Novartis investors turn spotlight on M&A after trial setbacks Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs it acquired through mergers and acquisitions hit its shares, raising concerns about its pipeline.
View source ↗ - Newsreuters.com·73d ago·Negative
Major Novartis shareholder calls for board shake-up after drug trial setbacks A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker's board to improve corporate governance after its shares suffered a record fall this week following back-to-back trial setbacks.
View source ↗ - Newszacks.com·74d ago·Neutral
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
View source ↗ - Newsprnewswire.com·74d ago·Neutral
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS) Novartis shareholders awoke to a more than 12.5% decline at open on September 8, 2026, after the Company reported that its Phase 3 HARBOR study of del-desiran and Phase 3 HORIZON study of pelacarsen did not meet their respective primary endpoints. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of NVS investors.
View source ↗ - Newsseekingalpha.com·74d ago·Neutral
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class Dyne Therapeutics remains a Buy despite a 16% selloff triggered by Novartis' DM1 trial failure, which heightened platform-wide clinical risk perceptions. The Novartis HARBOR trial failure challenges the core RNA-targeting therapeutic thesis, raising doubts about translating biomarker gains into functional benefit for DYN's DM1 and DMD programs. DYN's lead asset, z-rostudirsen, faces regulatory and confirmatory risks, w
View source ↗ - Newsbenzinga.com·75d ago·Neutral
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling Dyne Therapeutics Inc. (NASDAQ:DYN) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1).
View source ↗ - Newsreuters.com·75d ago·Negative
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapies for the tough-to-treat rare disease.
View source ↗ - Newsschaeffersresearch.com·75d ago·Neutral
Novartis Trial Failure Sparks Biopharma Options Frenzy Biopharma stocks are dominating the unusual options volume list today, after a high-profile clinical trial failure from Novartis AG (NYSE:NVS) sent shockwaves through the sector.
View source ↗ - Newsproactiveinvestors.com·75d ago·Negative
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR study evaluating the drug in myotonic dystrophy type 1. The study did not show a statistically significant improvement over placebo on video hand opening time, a novel measure of hand myotonia that served as the trial's primary endpoint.
View source ↗ - Newsinvestopedia.com·75d ago·Negative
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday U.S.-listed shares of Novartis are slumping Tuesday morning following disappointing clinical trial results from the Swiss drugmaker.
View source ↗ - Newsseekingalpha.com·75d ago·Negative
Novartis: 2 Significant Pipeline Setbacks Can Be Absorbed Novartis shares plunged after late-stage failures of pelacarsen and del-desiran, impacting its long-term growth outlook. Despite setbacks, Novartis reiterated 2025-2030 revenue growth guidance of 5-6% CAGR, aided by Rhapsido's phase 3 success in RMS. Rhapsido's positive data in relapsing multiple sclerosis offer partial offset, with potential for $3 billion+ in annual peak sales.
View source ↗ - Newscnbc.com·75d ago·Negative
'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat Sandoz CEO Richard Saynor warned U.S. patients could ultimately bear the cost of threatened tariffs on imported generic drugs. Saynor said manufacturers facing steep tariffs could be forced to raise prices or stop supplying some medicines.
View source ↗ - Newsbenzinga.com·75d ago·Neutral
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling over 400 points on Tuesday.
View source ↗ - Newsbenzinga.com·75d ago·Positive
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history.
View source ↗ - Newsinvezz.com·75d ago·Negative
Novartis stock falls 10% after second drug setback in a week; analyst cuts PT Novartis shares fell sharply on Tuesday after the Swiss drugmaker said its experimental treatment for myotonic dystrophy failed in a late-stage clinical trial, marking another setback for a pipeline that investors had been counting on to drive future growth. The stock fell about 10% following the announcement and has now lost more than 14% over the past five trading sessions.
View source ↗ - Newscnbc.com·75d ago·Negative
Pharma major plummets over 10% after third trial disappointment in a week Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
View source ↗ - Newsreuters.com·75d ago·Negative
Novartis announces trial setback on del-desiran drug Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug del-desiran's impact on myotonic dystrophy, a form of muscle wasting, had not met its target on a key metric, but reaffirmed its sales guidance through 2030.
View source ↗ - Newswsj.com·75d ago·Negative
Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial The drug candidate was one of three therapies the Swiss pharmaceutical company added to its pipeline through its $12 billion acquisition of Avidity Biosciences.
View source ↗ - Newszacks.com·76d ago·Negative
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
View source ↗ - Newswsj.com·76d ago·Negative
Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial The company said the late-stage study for its pelacarsen drug missed its primary objective of reducing the risk of cardiovascular events like death, heart attack and stroke compared with placebo.
View source ↗ - Newsreuters.com·76d ago·Negative
Novartis shares down as failed cholesterol drug study increases pipeline pressure Shares of Novartis fell 3.3% on Monday morning after its cholesterol drug failed in a closely watched study, casting fresh doubt on the therapeutic approach and raising the stakes for the Swiss drugmaker's upcoming data for a gene therapy.
View source ↗ - Newsbarrons.com·78d ago·Negative
A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares? In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.
View source ↗ - Newswsj.com·79d ago·Negative
A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study The Phase 3 study found a drug didn't reduce the risk of cardiovascular events like heart attacks and strokes.
View source ↗ - Newsglobenewswire.com·79d ago·Neutral
Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis' Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a comp
View source ↗ - Newswsj.com·79d ago·Negative
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint The company's shares declined in after-hours trading after the drug failed to reduce the risk of cardiovascular events in a Phase 3 study.
View source ↗ - Newsreuters.com·79d ago·Negative
Ionis, Novartis' key experimental heart drug fails in late-stage trial Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday.
View source ↗ - Newsbusinesswire.com·79d ago·Neutral
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocard
View source ↗ - Newsproactiveinvestors.co.uk·79d ago·Neutral
RBC backs Oxford BioMedica with 'outperform' rating amid Novartis trial halt Oxford BioMedica PLC (LSE:OXB) received a reaffirmed 'outperform' rating from RBC Capital Markets on Friday, as the broker shrugged off clinical trial halts at two heavyweight pharmaceutical partners. The shares inched up 1% to 430p in morning trade, with RBC holding its 900p target price and branding the clinical disruption as of limited direct financial relevance.
View source ↗ - News247wallst.com·80d ago·Positive
This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One Novartis just committed billions not to discover a new drug but to change how an existing one enters your body.
View source ↗ - Newszacks.com·81d ago·Negative
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies Novartis' remibrutinib delivers positive phase III RMS results, reducing relapse rates versus Aubagio and supporting plans for global regulatory approvals.
View source ↗ - Newsreuters.com·81d ago·Negative
Novartis could cut about 130 jobs in Basel site relocation Novartis could cut about 130 jobs in Switzerland as it relocates laboratory activities and shuts down some production in Basel, the Swiss drugmaker said on Wednesday.
View source ↗ - Newsproactiveinvestors.co.uk·81d ago·Positive
Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials Panmure Liberum has maintained its 'buy' rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its shares fell 15% following trial pauses by two of its customers. Novartis and Bristol Myers Squibb, both OXB customers, voluntarily paused enrolment in their autoimmune CAR-T programmes following safety issues.
View source ↗ - Newsinvestopedia.com·82d ago·Negative
Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping Promising results from a recent clinical trial are boosting Novartis shares this morning.
View source ↗ - Newsbarrons.com·82d ago·Positive
Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.
View source ↗ - Newsbarrons.com·82d ago·Negative
Sandisk, Marvell, Robinhood, Novartis, Dell, and More Stocks That Explain Today's Market AI stocks including Sandisk, Corning, and Intel struggle as investors ditch risk assets amid a run-up in bond yields.
View source ↗ - Newswsj.com·82d ago·Negative
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials Novartis shares rose after the drugmaker reported positive results in two late-stage trials from its new pill for the most common form of multiple sclerosis.
View source ↗ - Newsreuters.com·82d ago·Negative
Novartis' oral multiple sclerosis drug meets main goal in late stage studies Swiss drugmaker Novartis said on Tuesday that its oral drug, remibrutinib, met the main goals in two late-stage studies, showing superiority over a rival drug in reducing relapse rates in patients with a form of multiple sclerosis.
View source ↗ - Newsreuters.com·82d ago·Positive
Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died, the Wall Street Journal reported on Tuesday.
View source ↗ - Newswsj.com·82d ago·Positive
Novartis Pauses Autoimmune Cell Therapy Studies After Deaths Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died.
View source ↗ - News247wallst.com·95d ago·Neutral
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play Aktis Oncology (NASDAQ:AKTS) closed at $25.00 on August 18, 2026, giving the clinical-stage radiopharmaceutical company a market cap of $1.4 billion.
View source ↗
Earnings
Wed, Feb 3(in 2 months)
Consensus estimate $2.23 per share
Typical surprise +2.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Oct 27$2.46 vs $2.25beat
- Tue, Jul 21$2.41 vs $2.17beat
- Tue, Apr 28$1.99 vs $2.11miss
- Wed, Feb 4$2.03 vs $1.99beat
- Tue, Oct 28$2.25 vs $2.26miss
- Thu, Jul 17$2.42 vs $2.38beat
Estimates and results for NVS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (32d later)Sell$15,001 - $50,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$15,001 - $50,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (112d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (27d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (41d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (65d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (64d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (63d later)Buy$1,001 - $15,000
- George Whitesideshouse · CA27 · disclosed Apr 23, 2025 (30d later)Sell$100,001 - $250,000
- Sheldon Whitehousesenate · RI · disclosed May 20, 2024 (41d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (26d later)Buy$1,001 - $15,000
- Sheldon Whitehousesenate · RI · disclosed Oct 17, 2023 (27d later)Buy$15,001 - $50,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$50,001 - $100,000
- Thomas Richard Carpersenate · DE · disclosed May 1, 2023 (5d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (17d later)Buy$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
